Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Pharmacopeia has reported additional positive results from the company's Phase I multiple-ascending dose study of its lead internal product candidate for hypertension.
Subscribe to our email newsletter
PS433540 is a dual-acting angiotensin and endothelin receptor antagonist that is being developed as a potential treatment for hypertension and diabetic nephropathy. Data demonstrated that PS433540 produced statistically significant, dose-dependent increases in plasma-renin activity levels, as well as reductions in systolic and diastolic blood pressure.
These findings are in addition to previously reported initial results from the multiple-ascending dose trial that showed all doses of PS433540 to be safe and well-tolerated.
The trial’s positive plasma-renin activity and blood pressure findings provide preliminary insight into the potential of PS433540 to treat hypertension. Study investigators witnessed a dose-dependent increase in plasma-renin activity levels for PS433540, which was more pronounced at day 15 than at day one.
This observed increase in plasma-renin activity is indicative of PS433540’s ability to block the angiotensin receptor, a key target in efforts to lower and control blood pressure in hypertensive patients. Furthermore, associated with the increase in plasma-renin activity levels was a decrease in both diastolic and systolic blood pressure for PS433540 of up to 15mmHg.